Vector-Based RSV Vaccine Provides New Immunity Potential

A research group led by Gangyuan Ma explored the potential application of recombinant adeno-associated virus 5 (rAAV5) vector-based respiratory syncytial virus (RSV) vaccine. They focused on the pre-fusion (Pre-F) protein structure expression in intramuscularly immunized Balb/c mice and evaluated immunogenicity of the vaccine based on administration method: intranasal or intramuscular.

The rAAV5-RSV-Fm vaccine demonstrated positive humoral immunity and induced antibody titers against RSV strains A and B for up to 120 days after immunization. Of note, intranasal administration elicited protective antibodies and the study confirmed the superior immunogenicity of the vaccine’s Pre-F protein expression compared to full-length F protein.

These

A research group led by Gangyuan Ma explored the potential application of recombinant adeno-associated virus 5 (rAAV5) vector-based respiratory syncytial virus (RSV) vaccine. They focused on the pre-fusion (Pre-F) protein structure expression in intramuscularly immunized Balb/c mice and evaluated immunogenicity of the vaccine based on administration method: intranasal or intramuscular.

The rAAV5-RSV-Fm vaccine demonstrated positive humoral immunity and induced antibody titers against RSV strains A and B for up to 120 days after immunization. Of note, intranasal administration elicited protective antibodies and the study confirmed the superior immunogenicity of the vaccine’s Pre-F protein expression compared to full-length F protein.

These preliminary data highlight the potential application of rAAV5 vectors in RSV vaccine development and prompt further investigation into their protective efficacy.